731 related articles for article (PubMed ID: 34747190)
1. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Malek AE; Cornejo PP; Daoud N; Alam M
Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
[No Abstract] [Full Text] [Related]
2. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
Front Immunol; 2021; 12():800723. PubMed ID: 34992610
[TBL] [Abstract][Full Text] [Related]
3. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
4. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Montserrat E
Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
[No Abstract] [Full Text] [Related]
5. What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
Silvestris N
EBioMedicine; 2021 Dec; 74():103733. PubMed ID: 34864362
[No Abstract] [Full Text] [Related]
6. COVID-19 Vaccination Imperatives in People on Maintenance Dialysis: An International Perspective.
Blake PG; Hladunewich MA; Oliver MJ
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1746-1748. PubMed ID: 34281983
[No Abstract] [Full Text] [Related]
7. Three, four or more: what's the magic number for booster shots?
Watson C
Nature; 2022 Feb; 602(7895):17-18. PubMed ID: 35091715
[No Abstract] [Full Text] [Related]
8. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
9. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
Waissengrin B; Agbarya A; Safadi E; Padova H; Wolf I
Lancet Oncol; 2021 May; 22(5):581-583. PubMed ID: 33812495
[No Abstract] [Full Text] [Related]
10. Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials.
Korang SK; von Rohden E; Veroniki AA; Ong G; Ngalamika O; Siddiqui F; Juul S; Nielsen EE; Feinberg JB; Petersen JJ; Legart C; Kokogho A; Maagaard M; Klingenberg S; Thabane L; Bardach A; Ciapponi A; Thomsen AR; Jakobsen JC; Gluud C
PLoS One; 2022; 17(1):e0260733. PubMed ID: 35061702
[TBL] [Abstract][Full Text] [Related]
11. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
[No Abstract] [Full Text] [Related]
12. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
[TBL] [Abstract][Full Text] [Related]
14. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
15. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.
Mulhern JG; Fadia A; Patel R; Ficociello LH; Willetts J; Dahne-Steuber IA; Pollan MC; Mullon C; DeLisi J; Johnson C; Mysayphonh C; Kossmann RJ; Anger MS; Hymes JL
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1720-1722. PubMed ID: 34312162
[No Abstract] [Full Text] [Related]
16. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.
Barrière J; Carles M; Audigier-Valette C; Re D; Adjtoutah Z; Seitz-Polski B; Gounant V; Descamps D; Zalcman G
Eur J Cancer; 2022 Feb; 162():182-193. PubMed ID: 35016032
[TBL] [Abstract][Full Text] [Related]
17. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses.
Wisnewski AV; Liu J; Lucas C; Klein J; Iwasaki A; Cantley L; Fazen L; Campillo Luna J; Slade M; Redlich CA
PLoS One; 2022; 17(1):e0262657. PubMed ID: 35041700
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccination and cancer immunotherapy: should they stick together?
Brest P; Mograbi B; Hofman P; Milano G
Br J Cancer; 2022 Jan; 126(1):1-3. PubMed ID: 34799696
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine trials must include helminth-infected cohorts.
Egwang TG; Owalla TJ; Kemigisha M
Nat Immunol; 2022 Feb; 23(2):148. PubMed ID: 35075281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
